TSHA Stock Overview
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Taysha Gene Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.46 |
| 52 Week High | US$3.89 |
| 52 Week Low | US$0.50 |
| Beta | 0.26 |
| 1 Month Change | -24.31% |
| 3 Month Change | 67.35% |
| 1 Year Change | 285.88% |
| 3 Year Change | -89.87% |
| 5 Year Change | n/a |
| Change since IPO | -89.78% |
Recent News & Updates
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20
What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07We're Hopeful That Taysha Gene Therapies (NASDAQ:TSHA) Will Use Its Cash Wisely
Mar 08Taysha and UT Southwestern Medical Center launch innovation fund in gene therapy development push
Jan 13Taysha teams up with AllStripes to advance gene therapy in rare disorder
Jan 04Shareholder Returns
| TSHA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.5% | -2.5% | -3.2% |
| 1Y | 285.9% | -3.7% | 19.3% |
Return vs Industry: TSHA exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: TSHA exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| TSHA volatility | |
|---|---|
| TSHA Average Weekly Movement | 18.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TSHA's share price has been volatile over the past 3 months.
Volatility Over Time: TSHA's weekly volatility has decreased from 31% to 18% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 52 | Sean Nolan | www.tayshagtx.com |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center.
Taysha Gene Therapies, Inc. Fundamentals Summary
| TSHA fundamental statistics | |
|---|---|
| Market cap | US$460.06m |
| Earnings (TTM) | -US$111.57m |
| Revenue (TTM) | US$15.45m |
29.8x
P/S Ratio-4.1x
P/E RatioIs TSHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSHA income statement (TTM) | |
|---|---|
| Revenue | US$15.45m |
| Cost of Revenue | US$0 |
| Gross Profit | US$15.45m |
| Other Expenses | US$127.02m |
| Earnings | -US$111.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 100.00% |
| Net Profit Margin | -722.06% |
| Debt/Equity Ratio | 54.1% |
How did TSHA perform over the long term?
See historical performance and comparison